Results 31 to 40 of about 6,488 (202)
Puerarin as potential treatment in diabetic retinopathy [PDF]
, 2020 Diabetic retinopathy (DR) is one of the most prevalent microvascular complications of diabetes, and the most leading cause of visual loss around the world.
Mohammad Fathalipour +3 more
core +2 more sources
Chronopharmacokinetics of puerarin in diabetic rats
Indian Journal of Pharmaceutical Sciences, 2013 Puerarin injection has been widely used for clinic treatment of diabetes recently. To assess the relationship between the administration time of puerarin and the blood concentration of puerarin as well as its pharmacokinetic parameters, the diabetic rat model was used in current study.
Zhang, C. T. +4 more
openaire +3 more sources
Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism
Pharmaceutical Biology, 2020 Context Puerarin and astragaloside IV (AS-IV) are sometimes used together for the treatment of disease in Chinese clinics, however, the drug–drug interaction between puerarin and AS-IV is still unknown.
Huan Zhang +4 more
doaj +1 more source
Puerarin Alleviates Neuropathic Pain by Inhibiting Neuroinflammation in Spinal Cord [PDF]
, 2014 Neuropathic pain responds poorly to drug treatments, and partial relief is achieved in only about half of the patients. Puerarin, the main constituent of Puerariae Lobatae Radix, has been used extensively in China to treat hypertension and tumor.
Ming Liu +5 more
core +2 more sources
Journal of Orthopaedic Translation, 2022 Objective: Given the limitations of current anti-resorption agents for postmenopausal osteoporosis, there is a need for alternatives without impairing coupling crosstalk between bone resorption and bone formation ie. osteoclastogenesis.
Zuocheng Qiu +11 more
doaj +1 more source
Lipids in Health and Disease, 2023 Metabolic dysfunction-associated fatty liver disease (MAFLD) is frequently linked to type 2 diabetes mellitus (T2DM), and both conditions exacerbate the progression of the other. However, there is currently no standardized treatment or drug for MAFLD. In
Mengmeng Yang +14 more
doaj +1 more source
Puerarin attenuates pressure overload-induced cardiac hypertrophy [PDF]
, 2014 BackgroundPuerarin is the most abundant isoflavonoid in kudzu root. It has been used to treat angina pectoris and myocardial infarction clinically. However, little is known about the effect of puerarin on cardiac hypertrophy.MethodsAortic banding (AB ...
Yang, Zheng +9 more
core +1 more source
Shipin gongye ke-jiObjective: To prepare puerarin-Hericium insoluble dietary fiber composite microcapsules, and promote the research and development of puerarin related products by improving its embedding rate, antioxidant properties and bioaccessibility. Methods: Puerarin
Maolin LI +6 more
doaj +1 more source
Puerarin Exerts Protective Effects on Wear Particle-Induced Inflammatory Osteolysis
Frontiers in Pharmacology, 2019 Wear particle-stimulated inflammatory bone destruction and the consequent aseptic loosening remain major postoperative problems for artificial joints. Studies have indicated that puerarin promotes osteogenesis and alleviates lipopolysaccharide-induced ...
Chao Yang +6 more
doaj +1 more source
, 2014 Background Estrogen deficiency results in loss of bone mass. Phytoestrogens are plant-derived non-steroidal compounds with estrogen-like activity that bind to estrogen receptors.
孫瑞昇 +1 more
core +1 more source